Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform, today announced that it has appointed Dr Mike Burbridge, as Vice President, Oncology & Immuno-oncology.
Dr Gino Van Heeke, Engitix’s CSO said
“We are delighted to have attracted a scientist as high calibre as Mike, who has the experience and expertise to help push forward our internal therapeutic projects as well as our partnered programmes. His extensive knowledge will also be invaluable in supporting the company’s ambitious plans in oncology drug discovery and development.”
Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based on its proprietary human extracellular matrix (ECM) platform, today announced that it is relocating its headquarters and operations to WestWorks, White City Place (WCP).
The move follows announcements of high-profile collaboration agreements with Takeda Pharmaceuticals and Morphic Therapeutic, to leverage the benefits of Engitix’ human ECM-based discovery platform to improve the success rate of drug discovery and development.
This acknowledgement from two major players in the industry underpins the Company’s expansion, which starts with it moving to the 8,000 square feet facility of bespoke office and laboratory space in WCP.
Engitix Ltd: Engitix Therapeutics to Relocate Headquarters to New Life Sciences Cluster, White City Place
Engitix Ltd ( Engitix ), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based on its proprietary human extracellular matrix (ECM) platform, today announced that it is relocating its headquarters and operations to WestWorks, White City Place (WCP).
The move follows announcements of high-profile collaboration agreements with Takeda Pharmaceuticals and Morphic Therapeutic, to leverage the benefits of Engitix human ECM-based discovery platform to improve the success rate of drug discovery and development.
This acknowledgement from two major players in the industry underpins the Company s expansion, which starts with it moving to the 8,000 square feet facility of bespoke office and laboratory space in WCP.